Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to Metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
In a small-scale four-week long, open-label study involving 14 individuals diagnosed with major depressive disorder and bipolar disorder, which also displayed impaired executive function, treatment with liraglutide significantly reduced Hamilton Depression Rating Scale (HDRS) scores and improved executive function, however, at the same time it did not improve cognitive function in patients [122]
Reported side effects include skin rashes, abdominal pain (in rare instances), and temporary lightning in patches, which normalizes during treatment
Mimetics in Diabetes and Obesity Studies Obesity and overweight pose a significant global health concern, affecting millions of people, including both adults and children